Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lantus vs NPH Insulin in Children with Type 1 Diabetes
NCT01223131Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2011
- Primary completion
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoint: Absolute change of glycosylated hemoglobin (HbA1c) at 24 weeks. Started Feb 2011; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01223131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01223131.